This suggested that how to distinguish HER2-low breast cancer patients from HER2-positive or -negative patients is essential for decision-making regarding whether to receive anti-HER2 treatment and selecting appropriate types of anti-HER2 agents, e.g., T-DXd prescribed for HER2-low patients. This evidence concerns the gene ERBB2 and breast carcinoma.